Further development of local IL-2 therapy of cancer: Multiple versus single IL-2 treatment of transplanted murine colon carcinoma

Cancer Immunology, Immunotherapy

Volumn 53, Issue 5, 2004, Pages 445-452

  Kusnierczyk, Halina ^a   Pajtasz Piasecka, Elzbieta ^a   Koten, Jan Willem ^b   Bijleveld, Caspaar ^b   Krawczyk, Krzysztof ^c   Den Otter, Willem ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b Dept of Cell Biology and Histology ^*  (Netherlands)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Colonic neoplasms; Colonic neoplasms drug therapy; Interleukin 2 therapeutic use; Neoplasms therapy; Pathology

Indexed keywords

INTERLEUKIN 2; NITROUS OXIDE; RECOMBINANT INTERLEUKIN 2; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL INFILTRATION; CELL MIGRATION; CHEMOTAXIS; COLON CARCINOMA; CONTROLLED STUDY; DRUG INDICATION; EDEMA; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL CULTURE; COLON TUMOR; DBA MOUSE; DOSE RESPONSE; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; PATHOLOGY; TRANSPLANTATION;

ANIMALS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE; TUMOR CELLS, CULTURED;

EID: 2342530941     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0490-8     Document Type: Article

References (27)

1. Balemans LTM, Mattijssen V, Steerenberg PA, Van Driel BE, De Mulder PHM, Den Otter W (1993) Locoregional therapy with polyethyleneglycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pigs induces T-cell-mediated antitumor activity. Cancer Immunol Immunother 37:7
2. Balemans LT, Steerenberg PA, Koppenhagen FJ, Kremer BH, De Mulder PH, Claessen AM, Scheper RJ, Den Otter W (1994) PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide. Int J Cancer 58:871
3. Bancroft JD, Stevens A (1990) Theory and practice of histological techniques, 3rd edn. Churchill Livingstone, Edinburgh, pp 112 and 188
4. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W (2002) The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 51:492
5. Bastian NR, Yim C-Y, Hibbs JB Jr, Samlowski WE (1998) Induction of iron-nitric oxide EPR signals in murine cancers: effects of thiols and cytokine-induced oxidant stress. In: Lukiewicz S, Zweier JL (eds) Nitric oxide in transplant rejection and anti-tumor defence. Kluwer, Boston, p 295
6. Bubenik J, Perlmann P, Indrova M, Simova J, Jandlova T, Neuwirt J (1983) Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 14:205
7. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham J, Schnabel FM Jr (1975) A mouse colon-tumor model for experimental therapy. Cancer Chemother Rep 5:169
8. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35:2434
9. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Stewart R, Faber JAJ, Ruitenberg EJ, Rutten VPMG (1995) Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2:67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41:10
10. Den Otter W, De Groot JW, Bernsen MR, Heintz APM, Maas R, Hordijk GJ, Hill FWG, Klein WR, Ruitenberg EJ, Rutten VPMG (1996) Optimal regimes for local IL-2 tumor therapy. Int J Cancer 88:400
11. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M (1998) Intravesical interleukin-2 in T1 pappilary bladder carcinoma: regression of marker lesion in 8 out of 10 patients. J Urol 159:1183
12. Den Otter W, Cadée J, Gavhumende R, De Groot CJ, Hennink WE, Stewart R (1999) Effective cancer therapy with a single injection of interleukin-2 at the site of the tumor. Cancer Immunol Immunother 48:419
13. Everse LA, Bernsen MR, Dullens HF, Den Otter W (1996) The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of IL-2 administration. J Exp Ther Oncol 1:231
14. Everse LA, Bernsen MR, Dullens HF, Den Otter W (1997) Priming of the antitumor response promotes efficacy of interleukin-2 therapy. Cancer Immunol Immunother 44:221
15. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3
16. Janssen RAJ, Mulder NH, The TH, De Leij L (1994) The immunobiological effects of interleukin-2 in vivo. Cancer Immunol Immunother 39:207
17. Koten JW, Van Luyn MJA, Cadée JA, Brouwer L, Hennink WE, B C, Den Otter W (2003) IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine 24:57
18. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W (2001) A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 50:226
19. Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C (1999) Synergistic antitumor effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Med Oncol 16:267
20. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS (1997) Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57:3759
21. Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49:7037
22. Maas RA, Van Weering HJ, Dullens HFJ, Den Otter W (1991) Intratumoral low-dose interleukin-2 induces rejection of distant solid tumor. Cancer Immunol Immunother 33:389
23. NIH (1984) In vivo cancer models, 1976-1982. NIH Publication, No. 84. National Institutes of Health, Bethesda, MD, p 2635
24. Plonka B, Cieszka K, Plonka P, Pajak S, Raczek J, Lukiewicz S (1996) EPR signals detectable in the tumors of murine L578Y-R Lymphoma. Curr Top Biophs 20:81
25. Plonka P, Plonka B, Cieszka K, Raczek J, Lukiewicz S (1998) EPR analysis of tumor-host interactions. In: Lukiewicz S, Zweier JL (eds) Nitric oxide in transplant rejection and anti-tumor defence. Kluwer, Boston, p 313
26. Plonka P, Chlopicki S, Plonka B, Jawien J, Gryglewski R (1999) Endotoxaemia in rats: detection of nitroxyl-haemoglobin in blood and lung by EPR. Curr Top Biophs 23:47
27. Stewart RJG, Den Otter W, Hill FWG, Kock NC (1999) IL-2 therapy trials of ocular squamous cell carcinoma and vulval papilloma complex in cattle in Zimbabwe. Anticancer Res 19:2011